Troy is expressed in human stomach mucosa and a novel putative prognostic marker of intestinal type gastric cancer

Oncotarget

Volumn 8, Issue 31, 2017, Pages 50557-50569

  Wilhelm, Franziska ^a   Böger, Christine ^a   Krüger, Sandra ^a   Behrens, Hans Michael ^a   Röcken, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Differentiation; Gastric cancer; Stomach; Tnfrsf19 (Troy); Wnt signaling

Indexed keywords

MUCIN 5AC; TROY PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL STIMULATION; COLONY FORMATION; CONTROLLED STUDY; DIFFUSE TYPE GASTRIC CANCER; DISEASE MARKER; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GASTRIC CANCER CELL LINE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINAL TYPE GASTRIC CANCER; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MKN45 CELL LINE; MKN74 CELL LINE; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STAINING; STOMACH CANCER; STOMACH CHIEF CELL; STOMACH MUCOSA; STOMACH PARIETAL CELL; STROMA CELL; TRANSFECTED CELL LINE; TREATMENT OUTCOME; TROY GENE; TUMOR GENE; WNT SIGNALING PATHWAY;

EID: 85026629646     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10672     Document Type: Article

References (38)

1. Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015; 64: 1881-1888
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-386
3. Röcken C. Ways to personalized medicine for gastric cancer. Pathologe. 2013; 34: 403-412
4. Chiurillo MA. Role of the Wnt/beta-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med. 2015; 5: 84-102
5. Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J, Lowy AM. beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Research. 2002; 62: 3503-3506
6. Radulescu S, Ridgway RA, Cordero J, Athineos D, Salgueiro P, Poulsom R, Neumann J, Jung A, Patel S, Woodgett J, Barker N, Pritchard DM, Oien K, Sansom OJ. Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene. 2013; 32: 2048-2057
7. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513: 202-209
8. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, Chan KH, Chan AS, Tsui WY, Ho SL, Chan AK, Man JL, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nature Genetics. 2014; 46: 573-582
9. Fafilek B, Krausova M, Vojtechova M, Pospichalova V, Tumova L, Sloncova E, Huranova M, Stancikova J, Hlavata A, Svec J, Sedlacek R, Luksan O, Oliverius M, Voska L, Jirsa M, Paces J, et al. Troy, a tumor necrosis factor receptor family member, interacts with lgr5 to inhibit wnt signaling in intestinal stem cells. Gastroenterology. 2013; 144: 381-391
10. Munoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S, Volckmann R, Kung KS, Koster J, Radulescu S, Myant K, Versteeg R, Sansom OJ, van Es JH, Barker N, van Oudenaarden A, et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. The EMBO Jorunal. 2012; 31: 3079-3091
11. Kojima T, Morikawa Y, Copeland NG, Gilbert DJ, Jenkins NA, Senba E and Kitamura T. TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair follicles. Journal of Biological Chemistry. 2000; 275: 20742-20747
12. Eby MT, Jasmin A, Kumar A, Sharma K and Chaudhary PM. TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death. Journal of Biological Chemistry. 2000; 275: 15336-15342
13. Jacobs VL, Liu Y and De Leo JA. Propentofylline targets TROY, a novel microglial signaling pathway. PloS one. 2012; 7: e37955
14. Pispa J, Pummila M, Barker PA, Thesleff I and Mikkola ML. Edar and Troy signalling pathways act redundantly to regulate initiation of hair follicle development. Human Molecular Genetics. 2008; 17: 3380-3391
15. Ahmed Z, Mazibrada G, Seabright RJ, Dent RG, Berry M, Logan A. TACE-induced cleavage of NgR and p75NTR in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin. FASEB Journal. 2006; 20: 1939-1941
16. Park JB, Yiu G, Kaneko S, Wang J, Chang J, He XL, Garcia KC, He Z. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron. 2005; 45: 345-351
17. Paulino VM, Yang Z, Kloss J, Ennis MJ, Armstrong BA, Loftus JC, Tran NL. TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling. Molecular Cancer Research. 2010; 8: 1558-1567
18. Spanjaard RA, Whren KM, Graves C, Bhawan J. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. International Jorunal of Cancer. 2007; 120: 1304-1310
19. Zidi IT, M'Farrej S M, Bergaoui SD, Ghariani NZ, Bartegi AB, Ben Amor NN, Nouira RB. Tumor necrosis factorreceptor 2 and TROY gene expression patterns in cutaneous squamous cell carcinoma in a Tunisian population. Saudi Medical Journal. 2011; 32: 1202-1203
20. Schön S, Flierman I, Ofner A, Stahringer A, Holdt LM, Kolligs FT, Herbst A. beta-catenin regulates NF-kappaB activity via TNFRSF19 in colorectal cancer cells. International Jorunal of Cancer. 2014; 135: 1800-1811
21. Stange DE, Koo BK, Huch M, Sibbel G, Basak O, Lyubimova A, Kujala P, Bartfeld S, Koster J, Geahlen JH, Peters PJ, van Es JH, van de Wetering M, Mills JC, Clevers H. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell. 2013; 155: 357-368
22. Warneke VS, Behrens HM, Haag J, Kruger S, Simon E, Mathiak M, Ebert MP and Röcken C. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. British Jorunal of Cancer. 2013; 109: 2217-2227
23. Krausova M and Korinek V. Wnt signaling in adult intestinal stem cells and cancer. Cell Signaling. 2014; 26: 570-579
24. Clevers H, Loh KM and Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014; 346: 1248012
25. Schuijers J, Junker JP, Mokry M, Hatzis P, Koo BK, Sasselli V, van der Flier LG, Cuppen E, van Oudenaarden A, Clevers H. Ascl2 acts as an R-spondin/Wnt-responsive switch to control stemness in intestinal crypts. Cell stem cell. 2015; 16: 158-170
26. Klapholz-Brown Z, Walmsley GG, Nusse YM, Nusse R, Brown PO. Transcriptional program induced by Wnt protein in human fibroblasts suggests mechanisms for cell cooperativity in defining tissue microenvironments. PloS one. 2007; 2:e945
27. Loftus JC, Dhruv H, Tuncali S, Kloss J, Yang Z, Schumacher CA, Cao B, Williams BO, Eschbacher JM, Ross JT, Tran NL. TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance. Molecular Cancer Research. 2013; 11: 865-874
28. Ng A, Tan S, Singh G, Rizk P, Swathi Y, Tan TZ, Huang RY, Leushacke M and Barker N. Lgr5 marks stem/progenitor cells in ovary and tubal epithelia. Nature Cell Biology. 2014; 16: 745-757
29. Ebert MP, Yu J, Hoffmann J, Rocco A, Röcken C, Kahmann S, Müller O, Korc M, Sung JJ and Malfertheiner P. Loss of beta-catenin expression in metastatic gastric cancer. Journal of Clinical Oncology. 2003; 21: 1708-1714
30. Wu H, Whitfield TW, Gordon JA, Dobson JR, Tai PW, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis. Genome Biology. 2014; 15: R52
31. Qiu W, Hu Y, Andersen TE, Jafari A, Li N, Chen W, Kassem M. Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate of human mesenchymal (stromal) stem cells through canonical Wnt signaling and C/EBP. Journal of Biological Chemistry. 2010; 285: 14438-14449
32. Böger C, Behrens HM, Röcken C. Ki67-An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity. Journal of Surgical Oncology. 2016; 113: 46-54
33. Simon E, Petke D, Böger C, Behrens HM, Warneke V, Ebert M, Röcken C. The spatial distribution of LGR5+ cells correlates with gastric cancer progression. PLoSOne. 2012; 7: e35486
34. Lauren T. The two histologic main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta pathologica, microbiologica, et immunologica Scandinavica. 1965; 64:31-49
35. Sobin LH, Gospodarowicz M and Wittekind C. TNM Classification of Malignant Tumours: Wiley-Blackwell; 2009
36. McCarty KS, Jr., Miller LS, Cox EB, Konrath J, McCarty KS, Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives of Pathology and Laboratory Medicine. 1985; 109: 716-721
37. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C. Clonogenic assay of cells in vitro. Nature Protocols. 2006; 1: 2315-2319
38. Benjamini Y. Discovering the false discovery rate. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2010; 72: 405-416